CADTH Reimbursement Recommendation - Nelarabine (Atriance) - Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy
17 October 2023
Clinical experts are a critical part of the review team and are involved in all phases of the review process (e.g., providing guidance on the development of the review protocol, assisting in the critical appraisal of clinical evidence, interpreting the clinical relevance of the results, and providing guidance on the potential place in therapy). [...] The clinical experts indicated that the use of nelarabine in patients with newly diagnosed T-ALL is expected to increase the proportion of patients who achieve MRD-negative complete response and to decrease the proportion of patients who relapse (both extramedullary and marrow) during treatment. [...] In general, the clinical experts consulted for this review confirmed that the population of the COG AALL0434 trial was similar to patients seen in clinics, and there is no concern generalizing the findings from the trial to the Canadian clinical setting. [...] The clinical experts further noted that nelarabine can be prescribed to patients with T-ALL older than 30 years because the older the patient, the higher the risk of the disease. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.